Teva signs agreement with UNDP for procurement of drug to treat disseminated sclerosis
Teva pharmaceutical company (Teva Ukraine LLC) has signed a one-year agreement with the United Nations Development Programme (UNDP) to procure Glatirameri acetas to treat disseminated sclerosis. There is an option to extend the agreement for another two years.
The pharmaceutical company told Interfax-Ukraine that in 2018 and 2019 the UNDP would be able to order the medicine at once after adopting a resolution of the Cabinet of Ministers and signing the relevant agreement between the Health Ministry and the UNDP.
The company said that Teva could plan production and logistics, taking into account these orders.
"Taking this into consideration, and due to the large volume of procurement, Teva was able to offer a fixed price for Glatirameri acetas at a dose of 20 mg/ml and to ensure a gradual reduction in the price of Glatirameri acetas at a dose of 40 mg/ml in 2017 and subsequent years," the company said.
The company said that, thus, this agreement creates the conditions for providing Ukrainian patients with continuous access to quality therapy for three years.
"If the relevant changes in the legislation are made, the deal may be later transferred to a government agency that will manage public procurement and will be used to directly procure drugs by the state," Teva Ukraine said.
As reported, referring to the Health Ministry, the UNDP signed long-term agreements with four international manufacturers - Teva Pharmaceuticals (Israel), Pfizer (Netherlands), Novo Nordisk (Denmark) and Sanofi Genzyme (France) - for the supply of 11 drugs, including medicines for rare diseases such as multiple sclerosis, Gaucher's disease, mucopolysaccharides, cystic fibrosis, other orphan diseases, hemophilia, as well as medicines to stop bleeding.